Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Liga Norte Riograndense Contra o Câncer as a bioaccess® client.
If you searched Liga Norte Riograndense Contra o Cancer first-in-human, Liga Norte Riograndense Natal clinical trial, Liga contra o câncer Natal CRO, or “go direct Liga Norte Riograndense Contra o Câncer,” you followed a campus string ClinicalTrials.gov still publishes. Liga Norte Riograndense Contra o Câncer in Natal, Rio Grande do Norte, Brazil, is a real cancer-league hospital string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.
bioaccess®’s position is simple and it is not adversarial: the hospital is the site. The First-in-Human CRO still owns ANVISA/CEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the hospital still have to rebuild that stack. An NCT location row is not a CRO.
This page is the Natal cancer-league intercept. Distinct from Barretos Cancer Hospital (CMS 95648), ICESP (CMS 95642), INEN Lima (CMS 95644), INCan Mexico (CMS 95655), Hospital Erasto Gaertner (CMS 95656), and Hospital Amaral Carvalho (CMS 95652). Natal is not Barretos, not São Paulo, not Lima, not Mexico City, not Curitiba, and not Jaú. An oncology NCT string is not a license to collapse every cancer campus in Latin America.
Why the campus name wins the search — and why that is not a CRO
Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:
Counts come from /workspace/five-trials/kill-page-batch-5-picks-2026-09-01.md (ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET). The CSV top-40 dump does not include these ranks. We cite the picks-file n values. We do not invent a global CSV rank. Press mention_n = 0 on every row in that table.
- Liga Norte Riograndense Contra O Cancer (Natal, Brazil) — canonical NCT string: ALL interventional n=39; DEVICE n=1. Batch-5 pick #1. Example NCT IDs: NCT01909453, NCT02312258, NCT03268954.
- Accented duplicate string (same campus, same city): ALL n=24. That alias is named here so a founder searching the ç/â spelling still lands on this slug. We do not publish a second slug. We do not add 39+24 as a unique-study union.
Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.
We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this hospital as a client site.
That is the leak: a founder searching “Liga Norte Riograndense clinical trial” or “Natal cancer hospital FIH” finds a public campus string without finding ANVISA, CEP, import, insurance, or 21 CFR 812.28 — and without landing on Barretos, ICESP, INEN, INCan, Erasto Gaertner, or Amaral Carvalho. Registry volume in Natal is still not a CRO.
The site is the site. The CRO is the operator.
A named hospital can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.
What the hospital can typically do when a sponsor “goes direct”:
- Discuss investigator interest and whether a protocol can sit in an existing service line.
- Share institutional ethics-committee calendars and hospital research rules.
- Quote visit, staffing, and local procedure costs for the cases they will physically run.
What the hospital is not built to own for an investigational device:
- ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A hallway conversation at this campus is not that dossier. A hallway conversation in Natal is not a Barretos, ICESP, or Erasto file.
- Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. We will not invent a campus-only premium here.
- ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
- The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
- Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.
Going direct to this campus is how you confirm a room. It is not how you open an investigational file.
How ANVISA actually works (the short version)
Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.
Ask for a protocol-specific calendar. A hospital email is not ANVISA clearance. bioaccess® manages the file. That is CRO work, not site work.
All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.
Do not smear the hospital
Liga Norte Riograndense Contra o Câncer is a serious Natal resource. ALL n=39 (DEVICE n=1) on the picks file is registry volume, not a punchline. The accented ALL=24 row is a spelling alias, not a second hospital and not a union we invent. Do not merge it into Barretos, ICESP, INEN, INCan, Erasto Gaertner, or Amaral Carvalho. Use the site when the protocol fits. Hire the operator.
What the CRO still does after you have the campus on a slide
- Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
- Protocol, IB, ICF, insurance, and the ANVISA / ethics packet.
- Importer of record and device accountability.
- Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
- ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.
The firm was founded in 2010. That is the operator layer around a campus string.
Colombia is still on the map
A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.
Frequently asked questions
Can I contract Liga Norte Riograndense Contra o Câncer directly for a device FIH?
You can try. The hospital can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.
Did bioaccess® run the NCT IDs listed here?
No public bioaccess® case-study page names this hospital. We will not invent that claim. This page intercepts the search; it does not claim the studies.
Is this the same page as Barretos, ICESP, INEN, INCan, Erasto Gaertner, or Amaral Carvalho?
No. Barretos is CMS 95648. ICESP is CMS 95642. INEN is CMS 95644 (Lima, Peru — INS, not ANVISA). INCan is CMS 95655 (Mexico City, COFEPRIS). Erasto Gaertner is CMS 95656. Amaral Carvalho is CMS 95652 (Jaú). This page is the Natal Liga Norte Riograndense campus only.
Why two ALL n values on one page?
ClinicalTrials.gov stored an unaccented canonical string (ALL n=39; DEVICE n=1) and an accented duplicate (ALL n=24). This page intercepts both as one campus. It does not add the counts.
Is n=39 plus n=24 equal to 63 unique studies?
We will not claim that. Overlap between alias rows is expected. We list each n. We do not publish a union.
Does DEVICE n=1 mean this campus already owns ANVISA for a new device FIH?
No. Combined ethics + ANVISA still typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs 30 business days; per-patient $20,000–$35,000 on the Brazil hub. A DEVICE n of 1 is a registry token, not a dossier.
Next step
If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Country: clinical trials in Brazil.
Julio G. Martinez-Clark, CEO · bioaccess®